سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Faramarzi, Hossein, Hosseinpour, Ahmad, Sahebkar, Amirhossein, Khaloo, Vahid, Chamanpara, Parisa, Heydari, Mohammad Reza, Najafi, Sajad, Fotoohi Khankahdany, Fatemeh, Movahedpour, Ahmad. (1402). Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial. , 14(2), 215-228. doi: 10.22038/ajp.2023.23259
Hossein Faramarzi; Ahmad Hosseinpour; Amirhossein Sahebkar; Vahid Khaloo; Parisa Chamanpara; Mohammad Reza Heydari; Sajad Najafi; Fatemeh Fotoohi Khankahdany; Ahmad Movahedpour. "Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial". , 14, 2, 1402, 215-228. doi: 10.22038/ajp.2023.23259
Faramarzi, Hossein, Hosseinpour, Ahmad, Sahebkar, Amirhossein, Khaloo, Vahid, Chamanpara, Parisa, Heydari, Mohammad Reza, Najafi, Sajad, Fotoohi Khankahdany, Fatemeh, Movahedpour, Ahmad. (1402). 'Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial', , 14(2), pp. 215-228. doi: 10.22038/ajp.2023.23259
Faramarzi, Hossein, Hosseinpour, Ahmad, Sahebkar, Amirhossein, Khaloo, Vahid, Chamanpara, Parisa, Heydari, Mohammad Reza, Najafi, Sajad, Fotoohi Khankahdany, Fatemeh, Movahedpour, Ahmad. Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial. , 1402; 14(2): 215-228. doi: 10.22038/ajp.2023.23259

Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial

Avicenna Journal of Phytomedicine
دوره 14، شماره 2، خرداد و تیر 2024، صفحه 215-228    اصل مقاله (760.87 K)
نوع مقاله: Original Research Article
شناسه دیجیتال (DOI): 10.22038/ajp.2023.23259
نویسندگان
Hossein Faramarzi1؛ Ahmad Hosseinpour* 2؛ Amirhossein Sahebkar3؛ Vahid Khaloo4؛ Parisa Chamanpara5؛ Mohammad Reza Heydari6؛ Sajad Najafi7؛ Fatemeh Fotoohi Khankahdany2؛ Ahmad Movahedpour8
1Department of Community Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Shimi Teb Salamat Co., Shiraz, Iran
3Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
4Ali Asghar Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
5Department of Biostatistics, Shiraz University of Medical Sciences, Shiraz, Iran
6Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
7Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8Behbahan Faculty of Medical Sciences, Behbahan, Iran
چکیده
Objective: Despite an increasing number of studies, there is as yet no definite treatment developed for the coronavirus disease 2019 (COVID-19). In this clinical trial, we examined the efficacy of a novel herbal antiviral preparation in critically ill COVID-19 patients.
Materials and Methods: A total number of 120 ICU-admitted patients with a diagnosis of COVID-19 pneumonia were recruited to the trial. Participants were equally randomized to receive either the novel antiviral preparation sublingually, for up to two consecutive weeks or till discharge, or placebo. Clinical and laboratory parameters as well as survival rates were compared between the two groups.
Results: The cumulative incidence of death throughout the study period was 8.33% in the intervention group and 60% in the placebo group (risk ratio: 0.14; 95% confidence interval [CI], 0.05 to 0.32; p<0.001). On day 7, several parameters including white blood cells (WBCs) count, C-reactive protein, and SpO2 were improved for the treatment group compared with the placebo group (p-values of 0.05, 0.01, and <0.001, respectively).
Conclusion: This preparation might be suggested as a potentially promising COVID-19 treatment.
کلیدواژه‌ها
Coronavirus؛ SARS-CoV-2؛ COVID-19؛ Treatment؛ ICU Hospitalization؛ Mortality rate
آمار
تعداد مشاهده مقاله: 106,620
تعداد دریافت فایل اصل مقاله: 82,478